Aquestive Therapeutics, Inc. AQST

Aquestive Therapeutics resubmitted its New Drug Application to the FDA for Anaphylm (dibutepinephrine) Sublingual Film. NDA resubmission for lead candidate Anaphylm marks critical regulatory step with direct potential to enable product launch and revenue growth.

Aquestive Therapeutics gains renewed focus on Anaphylm as a potential treatment for anaphylaxis, presenting another shot at advancing this key product candidate toward regulatory and market success. Anaphylm success would mark a major strategic product advance capable of shifting company trajectory and investor outlook.

Aquestive Therapeutics released its Q2 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward-looking guidance. Earnings call transcripts disclose quarterly results and guidance that directly influence investor sentiment and stock valuation.

Aquestive Therapeutics discussed Anaphylm resubmission progress in its Q2 2026 earnings call. Anaphylm resubmission marks a key regulatory step for the company's primary product candidate.

Aquestive Therapeutics, Inc. presented its Q2 2026 earnings results and outlook during the earnings call. Q2 2026 earnings figures and forward guidance directly shape AQST valuation and investor positioning.

Aquestive Therapeutics reported Q2 financial results and provided operational updates during its earnings call. Quarterly earnings updates and guidance typically influence near-term stock sentiment without altering long-term trajectory.

Aquestive Therapeutics reported second quarter 2026 financial results and provided a business update. Quarterly results and business updates supply performance metrics that can move investor views and valuation.

Aquestive Therapeutics shares jumped on positive Anaphylm study results indicating strong efficacy and safety for the company's anaphylaxis treatment candidate. Positive Anaphylm study data triggered immediate share gains and signals major regulatory and commercial upside for the core pipeline asset.

Aquestive Therapeutics potential allergy film exhibited improvements in a human factors study. Positive human factors study results for allergy film candidate may moderately support product advancement and market sentiment.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) released first-quarter results, prompting analysts to issue new forecasts. First-quarter earnings release and revised analyst forecasts moderately influence financial performance and investor sentiment.

Aquestive Therapeutics Inc (AQST) reported a revenue surge and key strategic developments in its Q1 2026 earnings call, highlighting strong financial growth and future initiatives. Revenue surge and strategic highlights in Q1 2026 earnings represent major positive shifts in financial performance and competitive positioning for AQST.

Aquestive Therapeutics released Q1 earnings call highlights, covering financial results, pipeline updates, and forward guidance. Q1 earnings highlights reveal financial performance and outlook with moderate influence on investor sentiment and trajectory.

Aquestive Therapeutics reported Q1 2026 financial results in its earnings call, covering revenue, product pipeline updates, and forward-looking operational guidance. Quarterly earnings data and guidance directly inform near-term financial outlook and investor positioning for the company.

Aquestive Therapeutics (AQST) Q1 earnings are compared to analyst estimates, highlighting key metrics. Q1 earnings metrics versus estimates moderately influence AQST's financial performance and investor sentiment.

Aquestive Therapeutics (AQST) reported a Q1 net loss but beat revenue estimates. Q1 revenue beat despite loss moderately influences financial performance and market sentiment.

Aquestive Therapeutics reported first quarter 2026 financial results, including key revenue figures, net loss, cash position, and updates on pipeline progress for products like AnaphylmX, Libervant, and others, alongside business developments. Quarterly financial results and business updates moderately influence AQST's financial performance and investor sentiment.

Aquestive Therapeutics (AQST) completed a $150 million debt refinancing with Oaktree Capital Management, replacing prior debt with more favorable terms including a lower interest rate and extended maturity to 2029. Refinancing $150 million in debt lowers interest costs and extends maturities, significantly bolstering AQST's financial stability and market confidence.

Aquestive Therapeutics (AQST) awaits FDA approval for its Anaphylm NDA in Q3. Pending Q3 FDA approval for Anaphylm NDA could significantly enhance AQST's product pipeline and market valuation.

Aquestive Therapeutics completed a Type A meeting with the FDA for Anaphylm™ (dibutepinephrine) sublingual film, advancing its development for anaphylaxis treatment. Type A FDA meeting completion signals regulatory progress for Anaphylm, a key pipeline asset poised to disrupt epinephrine delivery and drive AQST growth.

Aquestive Therapeutics plans Q3 resubmission of Anaphylm NDA after FDA Complete Response Letter flags deficiencies in human factors validation study and pharmacokinetic data comparability. FDA CRL delays Anaphylm approval timeline to Q3, significantly impacting AQST's product pipeline and market performance.

Aquestive Therapeutics targets Q3 FDA resubmission for Anaphylm after receiving a Complete Response Letter and outlined detailed launch plans at the Leerink Conference. Q3 Anaphylm resubmission post-CRL and launch plans represent major regulatory progress and commercialization steps that could significantly boost AQST's market position.

Aquestive Therapeutics reported Q4 2023 revenue of $12.2 million, up 18% year-over-year, with full-year revenue at $58.0 million. Net loss narrowed to $3.2 million. Company reaffirmed 2024 revenue guidance of $65-68 million, highlighted Anaphylm NDA submission on track for FDA review, and noted $36.4 million cash position. Strong Q4 revenue growth, raised full-year outlook, and key Anaphylm progress position AQST for significant commercial expansion.

Aquestive Therapeutics, Inc. (AQST) released Q4 2025 earnings call summary highlighting financial results, pipeline updates, and future outlook. Q4 earnings call reveals financial performance, guidance, and strategic updates that significantly influence AQST's trajectory and investor sentiment.

Aquestive Therapeutics (AQST) Q4 2025 earnings call highlights revenue growth despite ongoing legal challenges. Revenue growth in Q4 earnings moderately boosts financial performance and market sentiment, offset by legal issues.

Aquestive Therapeutics (AQST) released Q4 earnings snapshot detailing financial results for the quarter. Q4 earnings snapshots reveal key financial metrics that significantly impact stock price and future outlook.

Aquestive Therapeutics, Inc. (AQST) reported fourth quarter and full year 2025 financial results and provided a business update. Financial results and business updates represent major events that significantly influence AQST's trajectory and investor sentiment.

Aquestive Therapeutics (AQST) Q4 earnings compared to estimates, with analysis of key metrics. Q4 earnings comparison to estimates influences AQST's financial performance and market sentiment.

Aquestive Therapeutics (AQST) reported a Q4 loss and missed revenue estimates. Q4 loss and revenue miss highlight weaker financial results, likely affecting short-term stock performance and investor sentiment.

Aquestive Therapeutics highlighted Anaphylm at the Oppenheimer Conference, targeting Q3 FDA resubmission after receiving a Complete Response Letter. Targeting Q3 FDA resubmission for Anaphylm after CRL represents a major regulatory milestone that could significantly boost AQST's product pipeline and investor sentiment.

Lake Street Capital Markets adjusted its valuation model for Aquestive Therapeutics (AQST), lowering the price target from $12 to $10 due to an expected delay in FDA approval for Anaphylm, while maintaining a Buy rating. Analyst valuation cut on expected FDA approval delay for flagship product Anaphylm poses significant risk to near-term revenue and stock performance.